CCNE1 overexpression
|
Hormone Receptor Positive Breast Cancer
|
CCNE1 overexpression
|
Hormone Receptor Positive Breast Cancer
|
palbociclib Resistant: B - Late Trials
|
palbociclib Resistant: B - Late Trials
|
CCNE1 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
CCNE1 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
CCNE1 overexpression
|
Ovarian Cancer
|
CCNE1 overexpression
|
Ovarian Cancer
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
CCNE1 overexpression
|
Endometrial Cancer
|
CCNE1 overexpression
|
Endometrial Cancer
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
CCNE1 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
CCNE1 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
RGT-419B Sensitive: D – Preclinical
|
RGT-419B Sensitive: D – Preclinical
|
CCNE1 overexpression
|
Ovarian Cancer
|
CCNE1 overexpression
|
Ovarian Cancer
|
SNS-032 Sensitive: D – Preclinical
|
SNS-032 Sensitive: D – Preclinical
|
CCNE1 overexpression
|
Triple Negative Breast Cancer
|
CCNE1 overexpression
|
Triple Negative Breast Cancer
|
AZD1775 + MK-4837 Sensitive: D – Preclinical
|
AZD1775 + MK-4837 Sensitive: D – Preclinical
|